[Para-aminosalicylic acid in the treatment of tuberculosis].

Mechanisms involved in the resistance of Mycobacterium tuberculosis to para-aminosalicylic acid.

That para-aminobenzoic acid antagonizes competitively the inhibitory effect of paraaminosalicylic acid on the growth of Mycobacterium tuberculosis is well known. In a previous communication (Hedgecock, 1956) it was reported that inhibition of M. tuberculosis (strain H37Rv) by para-aminosalicylic acid was reversed noncompetitively by methionine and biotin when the concentration of the inhibitor ...

Use of para-aminosalicylic acid in chronic pulmonary tuberculosis.

Antimycobacterial, antimicrobial, and biocompatibility properties of para-aminosalicylic acid with zinc layered hydroxide and Zn/Al layered double hydroxide nanocomposites

The treatment of tuberculosis by chemotherapy is complicated due to multiple drug prescriptions, long treatment duration, and adverse side effects. We report here for the first time an in vitro therapeutic effect of nanocomposites based on para-aminosalicylic acid with zinc layered hydroxide (PAS-ZLH) and zinc-aluminum layered double hydroxides (PAS-Zn/Al LDH), against mycobacteria, Gram-positi...

The continuous and concurrent use of streptomycin, para-aminosalicylic acid, isoniazid plus early surgery in the treatment of tuberculosis.

The development of resistant strains of tubercle organisms Is the main problem in using continuous antimicrobial therapy in the treatment of tuberculosis. Streptomycin and isonicotinic acid hydrazide have both been found to have a bactericidal action on tubercle organisms in the laboratory; the action of streptomycin varies directly with the concentration of the drug while the action of the iso...

Chlorpromazine in the control of side effects of para-aminosalicylic acid administration.

Courses of antituberculous chemotherapy are more prolonged than ever, and the problem of the unpleasant side effects of the administration of para-aminosalicylic acid (PAS) harasses both patient and physician for longer periods of time. Clinicians who manage tuberculosis are quite familiar with the difficulties entailed in keeping an appreciable number of their patients on an uninterrupted, pro...

HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues.

Para-aminosalicylic acid (PAS), an approved drug for treatment of tuberculosis, is a promising therapeutic agent for treatment of manganese (Mn)-induced parkinsonian syndromes. Lack of a quantifying method, however, has hindered the clinical evaluation of its efficacy and there upon new drug development. This study was aimed at developing a simple and effective method to quantify PAS and its ma...